CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade. uri icon

authors

  • von Roemeling, Christina
  • Ryu, Daniel
  • Grippen, Adam
  • Futch, Hunter
  • Ran, Yong
  • Hoang-Minh, Lan
  • Weidert, Frances
  • Todd Golde, MD, PhD
  • Mitchell, Duane
  • Yegorov, Oleg
  • Yang, Changlin
  • Klippel, Kelena
  • Russell, Rylynn
  • Trivedi, Vrunda
  • Bhatia, Alisha
  • Doonan, Bently
  • Carpenter, Savannah

publication date

  • November 14, 2023